Updates

Even low-level lead exposure in early childhood may speed up memory loss, according to a new study using a cognitive task to measure forgetting rates.

His vital signs in clinic were within normal limits, and the only additional finding at this time was a nontender, nonpruritic, and nonpalpable petechial rash on the bilateral lower extremities.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.